Merav Leiba

3.9k total citations · 1 hit paper
77 papers, 2.0k citations indexed

About

Merav Leiba is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Merav Leiba has authored 77 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hematology, 39 papers in Molecular Biology and 19 papers in Genetics. Recurrent topics in Merav Leiba's work include Multiple Myeloma Research and Treatments (38 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Protein Degradation and Inhibitors (12 papers). Merav Leiba is often cited by papers focused on Multiple Myeloma Research and Treatments (38 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Protein Degradation and Inhibitors (12 papers). Merav Leiba collaborates with scholars based in Israel, United States and Greece. Merav Leiba's co-authors include Arnon Nagler, Maya Koren‐Michowitz, Avichai Shimoni, Abraham Kneller, Raanan Berger, Rinat Rotem‐Yehudar, Adi Leiba, Olga Ostrovsky, Abraham Avigdor and Kihyun Kım and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Merav Leiba

75 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

2008 536 citations Raanan Berger, Merav Leiba et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Merav Leiba

Since Specialization

Citations

This map shows the geographic impact of Merav Leiba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Merav Leiba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Merav Leiba more than expected).

Fields of papers citing papers by Merav Leiba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Merav Leiba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Merav Leiba. The network helps show where Merav Leiba may publish in the future.

Co-authorship network of co-authors of Merav Leiba

This figure shows the co-authorship network connecting the top 25 collaborators of Merav Leiba. A scholar is included among the top collaborators of Merav Leiba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Merav Leiba. Merav Leiba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immature Platelet Fraction as a Surrogate Marker of Thrombo-Inflammation in Hospitalized COVID-19 Patients 2025 ·Life ·Adrian Duek, (unknown), (unknown), (unknown), (unknown), Merav Leiba	0
2	CyTOF profiling of bone marrow immune dynamics across myeloma stages 2025 ·OncoImmunology ·Dana Cholujová, (unknown), (unknown), Ľuboš Drgoňa, (unknown), Merav Leiba, Efstathios Kastritis, (unknown), (unknown), Jana Jakubı́ková	0
3	Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma 2023 ·Cells ·Olga Ostrovsky, Katia Beider, Hila Magen, Merav Leiba, Ralph D. Sanderson, Israël Vlodavsky, Arnon Nagler	2
4	Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia 2022 ·International Journal of Cancer ·Dana Cholujová, (unknown), Zachary R. Hunter, Teru Hideshima, Ludmila M. Flores, (unknown), (unknown), (unknown), Merav Leiba, Ľuboš Drgoňa, Steven P. Treon, Efstathios Kastritis, David M. Dorfman, Kenneth C. Anderson, Jana Jakubı́ková	5
5	Multiple Myeloma Presenting in Patients Younger than 50 Years of Age: A Single Institution Experience 2020 ·Acta Haematologica ·Adrian Duek, Luba Trakhtenbrot, Abraham Avigdor, Arnon Nagler, Merav Leiba	7
6	Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysis 2019 ·Clinical and Experimental Nephrology ·Olga Kukuy, Batia Kaplan, (unknown), Alexander Volkov, Adrian Duek, Merav Leiba, Ilan Ben‐Zvi, Avi Livneh	3
7	Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM) 2019 ·Blood ·Jonathan L. Kaufman, Saad Z. Usmani, Jesús F. San Miguel, Nizar J. Bahlis, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Maria Krevvata, Huiling Pei, Jon Ukropec, Thomas Renaud, Sonali Trivedi, Rachel Kobos, Meletios Α. Dimopoulos	28
8	Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome 2018 ·Leukemia Research ·Chezi Ganzel, Ory Rouvio, Irit Avivi, Hila Magen, (unknown), (unknown), Yossi Cohen, Tamar Tadmor, (unknown), Merav Leiba, Arnon Nagler, Yaël C. Cohen, Shlomo Bulvik, Aaron Polliack, Jacob M. Rowe, Moshe E. Gatt	10
9	Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy – a case series and review of the literature 2017 ·Amyloid ·Adir Shaulov, Irit Avivi, Yaël C. Cohen, Adrian Duek, Merav Leiba, Moshe E. Gatt	6
10	The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway 2016 ·Clinical Cancer Research ·Katia Beider, (unknown), (unknown), Avichai Shimoni, Merav Leiba, Maya Koren‐Michowitz, Elena Ribakovsky, Shiri Klein, Devorah Olam, Lola Weiss, Hanna Wald, Michal Abraham, Eithan Galun, Amnon Peled, (unknown)	33
11	Temporomandibular joint involvement in patients with multiple myeloma—a retrospective study 2016 ·International Journal of Oral and Maxillofacial Surgery ·(unknown), Ran Yahalom, Merav Leiba, Gahl Greenberg, Noam Yarom	1
12	High Normal Uric Acid Levels Are Associated with an Increased Risk of Diabetes in Lean, Normoglycemic Healthy Women 2016 ·The Journal of Clinical Endocrinology & Metabolism ·Michal Shani, Shlomo Vinker, Dganit Dinour, Merav Leiba, Gilad Twig, Eliezer J. Holtzman, Adi Leiba	43
13	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications 2011 ·Blood ·Jana Jakubı́ková, Sophia Adamia, Maria Kost‐Alimova, Steffen Klippel, David Cervi, John Daley, Dana Cholujová, Sun‐Young Kong, Merav Leiba, Simona Blotta, Melissa Ooi, Jake Delmore, Jacob P. Laubach, Paul G. Richardson, Ján Sedlák, Kenneth C. Anderson, Constantine S. Mitsiades	122
14	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma 2011 ·Haematologica ·Jana Jakubı́ková, David Cervi, Melissa Ooi, Kihyun Kım, Saifun Nahar, Steffen Klippel, Dana Cholujová, Merav Leiba, J F Daley, Jake Delmore, Joseph Negri, Simona Blotta, Douglas W. McMillin, Teru Hideshima, Paul G. Richardson, J Sedlák, K C Anderson, Constantine S. Mitsiades	63
15	Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia 2008 ·Differentiation ·(unknown), (unknown), (unknown), Merav Leiba, Arnon Nagler, Hanan Galski	9
16	Cyclosporine safety and bioavailability with two second-generation softgel capsules using serum concentrations/TDM and modeling in transplant patients a retrospective, parallel, comparative evaluation study 2008 ·International Journal of Clinical Pharmacology and Therapeutics ·Raanan Berger, (unknown), Merav Leiba, Abraham J. Domb, Arie Laor, Arnon Nagler	1
17	Changes in Gene Expression Pattern following Granulocyte Colony-Stimulating Factor Administration to Normal Stem Cell Sibling Donors 2006 ·Acta Haematologica ·Ninette Amariglio, Jasmine Jacob‐Hirsch, Avichai Shimoni, Merav Leiba, Gideon Rechavi, Arnon Nagler	22
18	Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease 2004 ·Annals of the Rheumatic Diseases ·Merav Leiba, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	90
19	Acute Respiratory Failure in a Patient with Sarcoidosis and Immunodeficiency?An Unusual Presentation and a Complicated Course 2004 ·Lung ·Adi Leiba, Sara Apter, Merav Leiba, Michael Thaler, Ehud Grossman	9
20	Behçet's disease and thrombophilia 2001 ·Annals of the Rheumatic Diseases ·Merav Leiba, (unknown), (unknown), (unknown), (unknown)	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact